Summary
Stryker Corporation's (SYK) Form 10-Q for the period ending June 30, 2010, reveals a robust financial performance characterized by significant revenue growth across both its Orthopaedic Implants and MedSurg Equipment segments. The company experienced an 8% increase in net sales for the second quarter and a 10% increase for the first half of 2010 compared to the prior year, driven by strong unit volume, favorable foreign currency exchange rates, and strategic acquisitions. Financially, Stryker demonstrated improved profitability with net earnings up 10% in the second quarter and 12% for the first half of the year. Operating income also saw a healthy increase of 15% and 16% for the respective periods. The company successfully managed its cost of sales, which decreased as a percentage of net sales, contributing to improved gross margins. Additionally, a significant event during the period was the issuance of $1 billion in senior unsecured notes, bolstering the company's liquidity and providing resources for future growth initiatives, including potential acquisitions and stock repurchases.
Financial Highlights
52 data points| Revenue | $1.76B |
| Cost of Revenue | $539.30M |
| Gross Profit | $1.22B |
| R&D Expenses | $94.60M |
| SG&A Expenses | $661.80M |
| Operating Expenses | $770.80M |
| Operating Income | $448.10M |
| Net Income | $319.00M |
| EPS (Basic) | $0.80 |
| EPS (Diluted) | $0.80 |
| Shares Outstanding (Basic) | 396.90M |
| Shares Outstanding (Diluted) | 399.20M |
Key Highlights
- 1Stryker reported an 8% increase in net sales for Q2 2010 ($1.76B) and a 10% increase for the first half of 2010 ($3.56B) compared to the prior year, indicating strong top-line growth.
- 2Net earnings increased by 10% in Q2 2010 ($319.0M) and 12% for the first half of 2010 ($640.7M), demonstrating improved profitability.
- 3Operating income grew significantly, up 15% in Q2 2010 and 16% for the first half of 2010, reflecting effective operational management.
- 4The company issued $1 billion in senior unsecured notes in January 2010, significantly increasing its cash and cash equivalents and bolstering liquidity to $785.2 million.
- 5MedSurg Equipment segment showed particularly strong growth, with sales up 16% for both Q2 and the first half of 2010 on a reported basis.
- 6Research, development, and engineering expenses increased by 15% in Q2 and 13% in the first half, signaling continued investment in innovation.
- 7The company addressed and resolved several FDA warning letters concerning manufacturing facilities, indicating progress in regulatory compliance.